Malcolm J. Sheardown

Author

Also Known As

M J Sheardown, M J. Sheardown, M. J. SHEARDOWN, M. J. Sheardown, M. SHEARDOWN, M. Sheardown, M.J. Sheardown, Malcolm J Sheardown, Malcolm J. Sheardown, Malcolm Sheardown

113

Publications

4.9K

Citations

H-Index

Concepts

All Affiliations

Novo Nordisk (Denmark)Eli Lilly (United States)Ferrosan Medical Devices (Denmark)University of Copenhagen St Thomas' Hospital

About

Malcolm J. Sheardown is an author at Novo Nordisk (Denmark) specializing in medicine, neuropharmacology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	28	40	3.2K
2	Social Sciences	14	15	992
3	Health Sciences	7	7	1.4K
4	Natural Sciences	5	5	274
5	Anesthesia	1	1	25

Malcolm J. Sheardown

Publications

4.8K

Citations

H-Index

Page 1

	Year	Citations
2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline: a Neuroprotectant for Cerebral Ischemia Malcolm J. Sheardown, Elsebet Ø. Nielsen, Anker Jón Hansen, Science PharmacotherapyDrug ResistanceBrain InjuryNeurologyIschemic Syndrome	1990	1.1K
Functional characterization of agonists at recombinant human 5‐HT<sub>2A</sub>, 5‐HT<sub>2B</sub> and 5‐HT<sub>2C</sub> receptors in CHO‐K1 cells Richard H. Porter, Karen Benwell, Helen Lamb, British Journal of Pharmacology	1999	354
Regional Changes in Interstitial K<sup>+</sup> and Ca<sup>2+</sup> Levels following Cortical Compression Contusion Trauma in Rats Pelle Nilsson, Lars Hillered, Yngve Olsson, Journal of Cerebral Blood Flow & Metabolism	1993	275
AMPA, but not NMDA, receptor antagonism is neuroprotective in gerbil global ischaemia, even when delayed 24 h Malcolm J. Sheardown, Peter D. Suzdak, Lars Nordholm European Journal of Pharmacology Gerbil Global IschaemiaNeurophysiologyMedicinePhysiologyNeuropharmacology	1993	192
ZK200775: A phosphonate quinoxalinedione AMPA antagonist for neuroprotection in stroke and trauma Lechosław Turski, Andreas Huth, Malcolm J. Sheardown, Proceedings of the National Academy of Sciences Pharmaceutical ScienceBioorganic ChemistryCerebrovascular DiseasePharmacotherapyPharmaceutical Chemistry	1998	167
Novel functional M1 selective muscarinic agonists. Synthesis and structure-activity relationships of 3-(1,2,5-thiadiazolyl)-1,2,5,6-tetrahydro-1-methylpyridines Per Sauerberg, Preben H. Olesen, Susanne Nielsen, Journal of Medicinal Chemistry	1992	162
Xanomeline, an M1/M4 preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice Harlan E. Shannon, Kurt Rasmussen, Frank P. Bymaster, Schizophrenia Research Antipsychotic-like ActivityPsychiatryMedicinePsychopharmacologyNeuropharmacology	2000	159
Sulfate content and specific glycosaminoglycan backbone of perlecan are critical for perlecan's enhancement of islet amyloid polypeptide (amylin) fibril formation. Gerardo M. Castillo, Joel A. Cummings, Wen Yang, Diabetes	1998	130
The Muscarinic Receptor Agonist Xanomeline Has an Antipsychotic-Like Profile in the Rat Kelly J. Stanhope, Nawazish Mirza, Mike Bickerdike, Journal of Pharmacology and Experimental Therapeutics	2001	129
Protection against ischemic hippocampal CAI damage in the rat with a new non-NMDA antagonist, NBQX Nils Henrik Diemer, Martin Balslev Jørgensen, Flemming Fryd Johansen, Acta Neurologica Scandinavica NeurotransmitterPharmacotherapyMin IschemiaRat ModelSocial Sciences	1992	107

Page 1